Targeting therapeutic transgene expression to defined tissues is a major task in the development of safe and efficient gene therapy protocols. Recombinant adenovirus is an attractive vector because it can be prepared in huge quantity and new generation vectors possess very large cloning capacities combined with reduced immunogenicity. In the brain, adenovirus transduces mainly glial cells, making it difficult to use this vector system in applications that need expression of therapeutic proteins in neurons. Here, we show that by using a small fragment of the human synapsin 1 gene promoter, we were able to restrict transgene expression from an adenoviral vector exclusively to neurons. Furthermore, we obtained stable long-term transgene expression from this vector in striatum and thalamus at appropriate vector dose.
Introduction
Gene therapy for slowly progressive diseases of the brain such as Alzheimer's or Parkinson's disease (PD) is a promising approach, with the prospect of first clinical trials in the near future. 1 To avoid deleterious side effects like malignant transformation by the long-term expression of therapeutic (eg anti-apoptotic) proteins in cell populations that are not directly affected by the diseases, it is important to strictly target transgene expression. Since neurons normally do not express functional MHC class I molecules and therefore do not present potential antigens even after fatal viral infection, 2, 3 neuronrestricted transgene expression has the added advantage of circumventing potential immune responses directed against the transgenes.
Recently, it has been convincingly demonstrated that adenoviral vectors do not necessarily evoke deleterious immune responses in the brain, thus allowing for persistent long-term transgene expression, [4] [5] [6] and several attempts have been made to restrict adenoviral vectormediated transgene expression to neurons. [7] [8] [9] Both the neuron-specific enolase (NSE) promoter and the addition of neuronal silencer elements to a ubiquitous promoter greatly improved neuronal targeting in the rodent brain, but there was still significant non-neuronal expression in about 20-30% of transduced cells. We, therefore, attempted to transcriptionally target long-term transgene expression exclusively to neurons in the central nervous system.
Promoters tested in terms of their expression kinetics were the human synapsin 1 gene promoter (in Ad.SY-N.EGFP), the rat NSE gene promoter (in Ad.NSE.EGFP), the human U1 snRNA promoter (in Ad.U1.EGFP) and the human cytomegalovirus promoter (in Ad.-CMV.EGFP). 10 The striatum and corpus callosum were chosen as targets since they do not consist primarily of neurons (like eg the dentate gyrus) but contain large amounts of glial cells. All vectors tested showed longterm expression in the striatum over 2.5 months, but only the synapsin promoter allowed for a virtually exclusive neuronal targeting.
As a feature very useful in gene transfer applications in the brain, adenoviral vectors are retrogradely transported in neurons. 11, 12 Thus, striatal vector application not only leads to gene expression in the striatum itself but also in dopaminergic neurons of the substantia nigra, which project to the striatum. The degeneration of these neurons constitutes the hallmark of PD, leading to severe implications in the control of motor circuits. We, therefore, investigated whether long-term adenoviral gene transfer is also possible in this neuronal population, as a fundamental basis for the generation of viral vectormediated animal models of this threatening disease. However, transgene expression in the retrogradely transduced substantia nigra rapidly ceased. This phenomenon was not due to a degeneration of the transduced neurons but rather appeared to originate from a loss of the viral genome.
Results

Human synapsin 1 gene promoter transcriptionaly targets adenoviral vectors exclusively to neurons
In order to evaluate the long-term expression characteristics of the various promoters, the respective vectors were injected into the striatum at a dose of 10 7 PFU each and brains were investigated for the transgene expression profiles after 2.5 months. We found that EGFP expression from the Ad.CMV.EGFP and the Ad.U1.EGFP vectors was virtually completely non-neuronal as revealed by a lack of concurrence with immunohistochemical staining for the neuron-specific antigen, NeuN (Figure 1d and f). The Ad.NSE.EGFP vector expressed the reporter gene in both, neurons and non-neuronal cells (Figure 1e ). About one-third of EGFP-labelled cells were found to be negative for the neuronal marker, NeuN, which is in good agreement with the recent findings of others. 7 In contrast, we detected EGFP fluorescence exclusively in NeuN-positive cells after transduction with the Ad.SYN.EGFP vector (Figure 1a-c) .
As an even more rigorous testing for neuronal restriction of transgene expression, vectors were injected into the white matter tract of the corpus callosum, which contains only very few neuronal cell bodies. We detected very strong EGFP expression from the CMV promoter in non-neuronal (NeuN negative) cells with glial morphology (Figure 1i ). Non-neuronal EGFP expression from the NSE promoter was drastically reduced as compared to the CMV promoter, although consistently detectable at 2.5 months after vector application (Figure 1h ). After application of Ad.SYN.EGFP, very little non-neuronal EGFP expression was detectable at the injection site at 7 days postinjection (not shown), and diminished to barely detectable levels at 2.5 months postinjection (Figure 1g) . Interestingly, as a distinguishing feature of the synapsin promoter, we were able to selectively label the rare interneurons (which show NeuN immunoreactivity) in the corpus callosum with the Ad.SYN.EGFP vector (Figure 1g ). Cortical neurons overlying the corpus callosum showed EGFP expression to a similar extent after both Ad.SYN.EGFP and Ad.NSE.EGFP injection (Figure 1g and h) .
In order to further clarify the general tropism of adenoviral vectors in the adult rat brain, we investigated whether non-neuronal expression took place in astrocytes or microglia, both of which have fibrous and ramified shapes. We mainly detected colocalization of the non-neuronal EGFP fluorescence with GFAP-positive cells (astrocytes), while nearly no such colocalization was observed with OX42-positive cells (microglia/resting macrophages) (Figure 2 ). Colocalization of EGFP with GFAP immunoreactivity occurred in the processes of the cells, where GFAP is mainly located, and thus allowed for a proper classification of these cells being astrocytes. No such correlation was seen when comparing EGFP expression with immunoreactivity for the cell surface antigen OX42 on microglial cells. These results are readily explained by the fact that astrocytes, but not microglial cells, express large amounts of receptors for adenovirus (coxsackie and adenovirus receptor, CAR and/or alpha V integrins). 13, 14 Appropriate vector dose ensured stable and long-term transgene expression without immunological consequences
We also investigated whether neuron-restricted transgene expression from the synapsin 1 gene promoter was dose dependent and stable over time. We injected rats with different doses of Ad.SYN.EGFP vector (either 10 6 , 10 7 , or 10 8 PFU) into the striatum and evaluated expression profiles after 7 days and 2.5 months, respectively. In all cases, EGFP expression was completely neuron restricted. We detected EGFP expression at 7 days after application of 10 6 PFU in three out of four animals (Figure 3a) , however, the amount of fluorescent cells and the transduction area were smaller as compared to injections of either 10 7 or 10 8 PFU of Ad.SYN.EGFP. Notably, the injection of 10 8 PFU did not lead to a pronounced increase in the number of EGFP-expressing neurons as compared to an injection of 10 7 PFU ( Figure  3b and c), indicating that the glial components of the striatum might capture most of the injected virus.
We did not observe immunological consequences (like microglia activation) after injection of up to 2 Â 10 7 PFU of either vector into the striatum (Figure 4a-d) . Microglial cells at the transduction sites retained their ramified shapes and did not proliferate into rounded, activated macrophages. However, application of 10 8 PFU of either adenoviral vector into the striatum of adult rats resulted in a pronounced immune response, as indicated by the observation of strong perivascular cuffing (Figure 4f ). 6, 15 At 2.5 months after injection of 10 8 PFU of Ad.SYN.EGFP, EGFP expression was no longer detectable but the accumulation of immune cells persisted (not shown), indicating that a too high vector dose may trigger deleterious immune reactions despite a completely neuron-restricted transgene expression.
No long-term transgene expression was achieved in dopaminergic neurons of the substantia nigra pars compacta (SNpC)
The expression of EGFP from the synapsin promoter appeared to be stable over the experimental time of 2.5 months in the striatum and thalamus. We detected very similar transduction areas and cell densities in both the brain areas at 7 days after transduction and at 2.5 months after transduction (Figure 3b, d and e-g ). These promising results prompted us to evaluate transgene expression in another clinically important area of the brain, the SNpC. Dopaminergic neurons from the SNpC project to the striatum and are important mediators of muscle tonus. The slowly progressive degeneration of these neurons is the hallmark of PD. Since recombinant adenovirus is retrogradely transported in neurons, the nigro-striatal projection can serve to introduce neuroprotective transgenes into the substantia nigra by intrastriatal injections. 12 We found efficient transduction of nigral neurons (as identified by immunoreactivity for tyrosine hydroxylase) in the SNpC of adult SD rats at 7
Neuron-specific long-term expression by hSYN promoter S Kügler et al days after intrastriatal injection of 10 7 PFU of either Ad.SYN.EGFP (Figure 5a-d, n¼3) , Ad.NSE.EGFP (n¼3; not shown) or Ad.CMV.EGFP (n¼3; not shown). However, in contrast to our findings in thalamus and striatum, we detected only very weak EGFP expression in the substantia nigra at 1 month after transduction ( In general, these results were confirmed with C57/B6 mice after intrastriatal injection of 10 7 PFU of Ad.SY-N.EGFP (S Rathke-Hartlieb, S Kü gler, unpublished results).
Dopaminergic neurons of the SNpC do not undergo degeneration upon adenoviral vector transduction
This remarkable decline in transgene expression might be due to several reasons: (i) dopaminergic neurons of ). There was a slight but insignificant reduction of tyrosine hydroxylase-positive neurons in the transduced SNpCs as compared to the contralateral SNpCs (Figure 5n ). However, the number of transduced cells as revealed by EGFP fluorescence (about 50% of the dopaminergic neurons) is much larger than the number of cells which might have degenerated at 2.5 months after transduction (less than 10%). Furthermore, the number of nigral tyrosine hydroxylase-positive neurons in the vector-transduced brains corresponds well with the number of nigral tyrosine hydroxylase-positive neurons in mock-injected brains (Figure 5n ), indicating that the majority of transduced dopaminergic neurons have not undergone degeneration.
To shed some further light on this apparent selfinactivation mechanism of adenoviral vectors in dopaminergic SNpC neurons, we injected 10 7 PFU of Ad.-SYN.EGFP directly into the substantia nigra region. In concordance with the results obtained after retrograde nigral transduction, we detected EGFP expression in dopaminergic neurons both in the proximity of the needle tract (Figure 6a -f) and at larger distances from the needle tract (not shown) at 7 days after transduction, while at 1 month after transduction there was nearly no transgene expression detectable in dopaminergic neurons. Outside the substantia nigra, neuronal EGFP expression was readily detectable (Figure 6g-i) , just as in the other brain regions investigated. We also investigated some rats at 2.5 months after intranigral injection and in one animal detected pronounced EGFP expression very close to the needle tract. However, a vast majority of these cells were not immunoreactive for tyrosine hydroxylase (Figure 6k-p) . Inspection of the contralateral substantia nigra revealed that the amount of tyrosine hydroxylase-positive neurons was equal in the transduced and in the contralateral area, ruling out the possibility that the transduced cells simply have lost their tyrosine hydroxylase immunoreactivity (Figure 6q s). It should be noted that such intranigral transgene expression in non-dopaminergic neurons at time points 1 or 2.5 months was confined to only one out of five Neuron-specific long-term expression by hSYN promoter S Kügler et al animals investigated, and furthermore was restricted to only some sections in very close proximity to the needle tract.
Adenoviral vector genomes are lost in dopaminergic neurons of the SNpC
Since obviously dopaminergic neurons survived adenoviral transduction but concurrently did not allow for persistent transgene expression, we investigated whether the adenoviral genome was stable in these neurons. We designed a sensitive PCR system amplifying a 100 bp fragment from the 3 0 end of the transgene expression cassette. Total DNA was extracted from brain slices of animals either 8 days or 2.5 months after striatal (right side) transduction, and of animals at 2.5 months after intranigral (right side) transduction (n¼2 or 3 for each condition). We could readily amplify the expected PCR fragment from the striatum both at 8 days (Figure 7c ) and 2.5 months after striatal transduction (Figure 7b ) and at 2.5 months after intranigral transduction (Figure 7a) . Since immunohistochemistry has shown that after intranigral vector application, transgene expression is virtually completely extranigral at 2.5 months after transduction, the amplified vector genomes most likely were derived from non-dopaminergic cells outside the SNpC. Strikingly, we obtained only marginal amplification product from the substantia nigra at 2.5 months after striatal transduction (Figure 7b) , while the prominent Figure 3 Stable long-term expression driven by the human synapsin 1 gene promoter in striatum and thalamus. Ad.SYN.EGFP was injected into the anterior part of the striatum at either 10 6 PFU (n¼4); 10 7 PFU (n¼4) or 10 8 PFU, (n¼3) and EGFP fluorescence was recorded in this area (a-d) or was injected into the posterior striatum/globus pallidus area at 10 7 PFU, (n¼6) and EGFP fluorescence was recorded in the laterodorsal thalamus (e-g) at the indicated times (7 days, 1 month and 2.5 months after transduction). Representative sections (16 mm) situated beneath the needle tracts are shown. Scale bar¼400 mm in (a-d), 100 mm in (e-g).
Neuron-specific long-term expression by hSYN promoter S Kügler et al amplification product was detected from the nigra at 8 days after striatal transduction (Figure 7c ), indicating that the viral genome including the transgene expression cassette is specifically lost in dopaminergic substantia nigra neurons.
Discussion
The recent development of improved adenoviral vector technology (the so-called 'gutless' adenovirus; lacking all viral genes but being dependent on a helper virus during production) has raised new hope to be able to use this vector in clinical therapies in the human brain. 16, 17 As an other important advancement in adenoviral vector applications, we demonstrated in this study that the vector can be transcriptionaly targeted exclusively to neurons by using a short fragment of a human gene derived promoter. The human synapsin 1 gene promoter appeared to be a highly suited pan-neuronal promoter, which readily outperformed the recently described transcriptional targeting approaches. 7, 8 The selective neuronal transgene expression in an environment nearly exclusively composed of non-neuronal cells (the white matter tract of the corpus callosum) impressively demonstrated the unsurpassed neuronal specificity of the synapsin 1 gene promoter. This promoter showed the highest degree of long-term neuronal restriction observed from an adenoviral vector in vivo so far. Its usability is further extended by the recent finding of Glover et al., who demonstrated that by adding the woodchuck hepatitis post-transcriptional element (WPRE) to a synapsin promoter-driven expression cassette, promoter strength is significantly enhanced without affecting its neuronal specificity. 18 In this study, we used adenoviral vectors only deleted in the E1 region (first-generation vectors). Nevertheless, we detected sustained long-term transgene expression from these vectors, regardless of whether expression of the heterologous transgene took place in glia, neurons or both. Thus, these relatively simple gene transfer vectors are well-suited vehicles for the evaluation of experimental therapeutic strategies in the brain, avoiding the somewhat tedious procedure of helper-dependent adenoviral vector production. It should be kept in mind that these vectors retained their E3 region in the vector genome. Thus, if any leaky expression from the viral genome may occur, then it is likely that E3 genes are also transcribed, leading to a low level but probably advantageous expression of immunomodulatory proteins. 19 Furthermore, the nature of the expressed transgene may have an influence on immune responses to adenoviral vectors: it has been shown in the rat retina that a vector expressing b-galactosidase but not vectors 
n¼3). EGFP fluorescence was recorded in (a, c). Microglial reaction to long-term transgene expression was evaluated by staining for the microglial/macrophage antigen OX42 (b, d).
The overall tissue reaction to elevated vector dosage was documented by DAPI staining (e, f). Arrows in (f) point to areas of strong perivascular cuffing. CC, corpus callosum, CPu, caudate putamen (striatum). In parts (a)-(d) OX42 immunoreactivity is shown at 2.5 months after transduction, an identical outcome was found at 7 days after transduction (not shown). In parts (e-f) the tissue reaction is shown at 7 days after transduction, an identical result was found at 2.5 months after transduction (not shown).
Neuron-specific long-term expression by hSYN promoter S Kügler et al coding for autologous neurotrophins caused immunological consequences. 20 Our data clearly show that adenoviral vectors infect both neurons and glia in the rat brain. The targeting of the vectors as described here is based on transcriptional control mechanisms. After cerebral injection, the synapsin promoter expressed exclusively in neurons, while the CMV promoter expressed nearly exclusively in glial cells (with the exception of microglia). However, this does not mean that the CMV promoter is generally inactive in neurons: after retrograde transduction of neuronal populations (either in the SNpC or the retina), the CMV promoter expressed transgenes in the respective neurons. 11, 12 Apparently, as it has been demonstrated in cocultures of primary neurons with glial cells as well, the simultaneous infection of neurons and glia leads to a suppression of the CMV promoter in neurons while it is highly active in non-neuronal cells. 10 We have observed this phenomenon with other vector types also: a double promoter AAV-2 vector (synapsin and CMV promoters) expressed the synapsin-driven transgene exclusively in neurons but the CMV-driven transgene nearly exclusively in glial cells when used in vitro in coculture of hippocampal neurons and glial feeder cells (S Kü gler, unpublished observation).
In accordance with the results obtained with adenoviral vectors expressing in glial cells, 6 we clearly detected a threshold dose (42 Â 10 7 PFU in SD rats) which sets the upper limit of viral particles that could be administered to the rat brain without causing inflammation and elimination of transduced cells. This was true even if transgene expression was completely neuron specific. Interestingly, using higher dosages of Ad.SYN.EGFP in the striatum (10 8 PFU instead of 10 7 PFU) did not lead to enhanced transduction efficiencies. This might be due to the onset of inflammation but also may result from saturation effects of the adenoviral receptors on neurons. Thus, the main obstacle of adenovirus (either firstgeneration or gutless vectors) mediated gene transfer to the brain seems to be the large amount of receptors (CAR Neuron-specific long-term expression by hSYN promoter S Kügler et al Figure 6 Vector application directly into the substantia nigra reveals attenuation of transgene expression specifically in dopaminergic neurons. EGFP expression was investigated at either 7 days (a-f; n¼2), 1 month (g-i; n¼2) or 2.5 months (k-s; n¼3) after intranigral transduction with 10 7 PFU of Ad.SYN.EGFP. The left column of the figure shows tyrosine hydroxylase immunoreactivity, the centre column shows EGFP fluorescence and the right column shows the respective multiple exposures. In (c), (i), (m) and (s) the nuclear DAPI stain is also included to accentuate the needle tract (arrows in (c) and (m)) and to demonstrate the absence of inflammation. Rectangles in low-power micrographs (k-m) denote the display window shown in the high power micrographs (n-p) which are rotated by about 901. Arrowheads in (f) and (p) indicate neurons showing EGFP fluorescence but no tyrosine hydroxylase immunoreactivity. Note that parts (k-s) show a singular occurrence, in all other brains investigated at both 1 and 2.5 months after transduction virtually no EGFP fluorescence was detected in the sNpC.
Neuron-specific long-term expression by hSYN promoter S Kügler et al and/or integrins) on astrocytes, 13 which apparently capture most of the injected viral particles. While it has been possible to achieve detectable reporter gene expression in glial cells with vector dosages below 10 4 PFU, 5 we have found that at least 10 6 PFU of Ad.SYN.EGFP were necessary to achieve neuron-specific expression in more than only a few cells. Striatal transduction with only 10 4 or 10 5 PFU of Ad.SYN.EGFP did not lead to detectable EGFP expression at 2.5 months after transduction (data not shown).
After having demonstrated long-term, non-immunogenic and highly neuron-specific transgene expression in striatum, thalamus and even in the corpus callosum from the Ad.SYN.EGFP vector, we aimed to investigate the properties of this vector in a clinically highly relevant area of the brain, the substantia nigra. Dopaminergic neurons of the SNpC projecting to the striatum are necessary mediators of muscle tonus. The slow degeneration of these neuronal subpopulation constitutes the hallmark of PD. It would be beneficial to be able to express proteins relevant for PD in these neurons over prolonged periods of time in order to obtain an animal model of slowly progressive degeneration. However, we did not achieve transgene expression substantially longer than 1 week in the dopaminergic neurons of the SNpC, neither by retrograde transduction (after striatal vector application) nor by direct intranigral vector injection.
Counting of dopaminergic neurons in both the ipsilateral and the contralateral nigra at 2.5 months after striatal transduction (and subsequent retrograde transport of the vectors to the substantia nigra) revealed that no significant cell loss had occurred. Thus, vectormediated toxicity apparently did not lead to diminished transgene expression. Intranigral injection of Ad.SY-N.EGFP showed the same phenomenon: transgene expression was detectable in dopaminergic neurons only after 7 days but not after 1 month. These results rule out the possibility that the retrograde transport of the viral particles is responsible for their short-term expression. Interestingly, extranigral expression (resulting from spreading of the vector to adjacent regions) was as neuron specific and persistent as in striatum and thalamus. In one animal, we even detected EGFP expression in neurons located directly in or adjacent to the SNpC, the majority of which, however, did not show immunoreactivity for tyrosine hydroxylase. These neurons may either be stellate, non-dopaminergic interneurons of the SNpC or, more likely, neurons of the small nuclei of the ventral parts of the thalamus. 21 However, the fact that they show transgene expression at 2.5 months after adenoviral transduction, while most of the contiguous dopaminergic neurons do not, clearly illustrates the selective attenuation of adenoviral gene expression in dopaminergic neurons of the SNpC.
As a plausible reason for this unusual attenuation of transgene expression, we found that the viral genomes did not persist in the dopaminergic neurons of the SNpC at 2.5 months after striatal transduction. We used a semiquantitative PCR amplification of the viral backbone DNA in order to estimate whether the viral genomes were stable in the transduced cells. The drastical reduction of the viral genomes present in the SNpC at 2.5 months after striatal vector injection (and subsequent retrograde transport to the SNpC) as compared to 8 days after transduction is clearly evident. Note that the PCR product amplified from directly transduced nigrae is derived from the extranigral transduction, as it is impossible to isolate specifically the SNpC tissue without coisolation of substantial amounts of surrounding tissue. Furthermore, PCR products obtained from striatum after striatal vector application (and from nigra after nigral vector application) did not result from neurons alone but also from transduced astrocytes (which do not express the transgene, but contain the viral genome). In contrast, Figure 7 Adenoviral genomes are lost in retrogradely transduced substantia nigra. Amplification of a 100 bp fragment of the vector transgene expression cassette out of genomic DNA isolated from the indicated tissues at either 2.5 months after intranigral vector injection (a), at 2.5 months after striatal vector injection (b) or at 8 days after striatal vector injection (c). The lower panel shows the DNA loading standard. Asterisks indicate the most important fragments, showing that the vector genome can readily be detected in the substantia nigra at 8 days after striatal application but appears to be drastically diminished in the substantia nigra at 2.5 months after striatal vector application. M, molecular weight markers; X, no DNA control.
Neuron-specific long-term expression by hSYN promoter S Kügler et al PCR products obtained from the SNpC after striatal vector application can only be derived from the dopaminergic neurons of the SNpC, since only these neurons project to the striatum and thus are retrogradely transduced. Therefore, only the two PCR products marked by asterisks in Figure 7 can be directly compared and allow for an estimation of the vector genome loss.
The mechanism leading to this ''self-inactivation'' of adenoviral vectors, specifically in the dopaminergic neurons of the SNpC, remains elusive. Since long-term EGFP expression from an adeno-associated vector was achieved in dopaminergic neurons of the SNpC, 1 a detrimental influence of this transgene appears unlikely. It remains to be evaluated whether the viral backbone has any influence on this process (eg whether gutless genomes are also lost) or whether the dopaminergic neurons of the ventral tegmental area respond to adenoviral transduction in a similar manner. None theless, a self-inactivating vector system might offer the opportunity to study the effects of a relatively short-term expression of protective proteins on the long-term therapeutical outcome.
The synapsin promoter might also be exceptionally useful in other vector systems like herpes simplex virus (HSV), adeno-associated virus (AAV) and lentivirus (HIV/FIV), in order to completely restrict transgene expression to neurons. The NSE promoter has shown poor expression in an HSV system but very good neuronal specificity in an AAV vector injected into the spinal cord of adult rats. 22, 23 However, this promoter fragment (about 1800 bp) occupies about 40% of the cloning capacity of AAV and might therefore be replaced by the much smaller synapsin 1 gene promoter (about 470 bp). AAV-2 vectors are highly neuron specific per se and thus may mainly benefit from the promoter size reduction. AAV-5 vectors, however, which are able to transduce much larger areas of the brain and retina than the AAV-2 serotype, 24, 25 but are not neuron specific, may be targeted to neurons in a similar way than adenoviral vectors.
In conclusion, we have demonstrated that a short fragment of the human synapsin 1 gene promoter is capable of restricting transgene expression virtually completely to neurons, even in a vector system which efficiently transduces the non-neuronal cells of the brain. This promoter is clearly superior to recently published neuron-restricted promoters, which showed significant residual activity in non-neuronal cells. 7, 8 The fact that a human promoter element allows for long-term transgene expression in the rodent brain raises hope that this promoter may also become a standard promoter for gene therapy approaches in the brain of non-human primates and even man.
Materials and methods
Vectors
Construction of E1-deleted replication-deficient recombinant adenoviral vectors expressing EGFP under control of either the human synapsin 1 gene promoter (B470 bp; Ad.SYN.EGFP), the human cytomegalovirus promoter (B600 bp; Ad.CMV.EGFP), the human U1 snRNA gene promoter (B400 bp; Ad.U1.EGFP) or the murine NSE gene promoter (B1800 bp; Ad.NSE.EGFP) has been described, and the same vector preparations, which have been used for the recently described in vitro experiments, were used in the in vivo study presented here. 10 Vectors were raised in 293S suspension cells, purified by two rounds of CsCl gradient centrifugation, dialysed 4 Â against 500 volumes of PBS/10% glycerol and titrated by plaque assay on 293 cells (quadruple determinations for each dilution). RCA was tested by semiquantitative PCR and was below the detection limit of 1:10 6 . Endotoxin levels were negligible (below 0.005 IE/ ml) as determined with quantitative chromogenic LAL assay.
Sterotaxic injections
Stereotaxic injections were performed according to the coordinates given by Paxinos and Watson. 26 Female SD rats of 260-280 g body weight were used. Anaesthesia of animals was performed by intraperitoneal injection of chloralhydrate (420 mg/kg), they were then placed into a stereotaxic frame (Stoelting, Wood Dale, IL, USA) and through a small burr hole were injected by means of a 10 ml Hamilton series 700 syringe, point style 2, which was mounted to a step motor. A volume of 2 ml was injected over a period of 5 min, the needle was left in place for further 5 min and then was slowly withdrawn. The co-ordinates were: central striatum: bregma 0, lateral 3 mm and 4.3 mm below dura; posterior striatum/globus pallidus: bregma À1.8 mm, lateral 4 mm and 4.5 mm below dura; corpus callosum: bregma 1.7 mm, lateral 2 mm and 3 mm below dura; substantia nigra: bregma À5.3 mm, lateral 2.4 mm and 7.3 mm below dura.
Immunohistochemistry and cell counts
Animals were intracardially perfused with 4% paraformaldehyde after receiving a lethal dose of chloralhydrate. Brains were removed, postfixed and cryoprotected in 30% sucrose. Sections of 16 mm thickness were cut on a cryostat (Leica, Nussloch, FRG), mounted on object slides and stored at À801C until analysis. Immunofluorescent staining was performed with the following antibodies: monoclonal anti-NeuN 1:100 (Mab377, Chemicon, Temecula, USA), polyclonal anti-GFAP 1:1000 (DAKO, Hamburg, FRG), monoclonal anti-OX42 (CD11b) 1:250 (Serotec, Kidlington, UK), monoclonal antithyrosine hydroxylase 1:100 (DiaSorin, Stillwater, UK). A Cy3-labelled secondary antibody (Rockland, Gilbertsville, USA) was used for detection, and images were taken on a Zeiss Axioplan 2 microscope equipped with a CCD camera.
Counting of tyrosine hydroxylase-positive (TH+) nigral neurons was performed on randomly selected sections (4-6/animal), spatial arrangement of hippocampal dentate gyrus and CA1-3 regions served to identify whether the sections were in a true horizontal plane. Only sections derived from animals showing strong striatal EGFP expression were used in order to verify that retrograde transport to the substantia nigra has occurred. Zeiss AxioVision software was used to determine cell numbers and the area of the SNpC.
Statistical analysis was performed by Student's unpaired t-test and values expressed as mean7standard deviation.
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Amplification of recombinant adenoviral genomes
Transduced tissue was prepared from unfixed brains by cutting 1 mm slices in the coronal plane. Tissue samples from the left (contalateral) and right (injected) striata (50-60 mg) and the left and right nigrae (35-45 mg) were prepared and proteolytically digested. DNA was isolated by RNase digestion, phenol/chloroform extractions and subsequent purification by silica spin columns (DNA quick spin kit, Qiagen, Hilden, FRG). DNA concentrations were measured spectrophotometricaly and equal amounts (25 ng) were used for amplification of the recombinant adenoviral genome. Primers for nested PCR were placed into the chimeric intron and SV40 polyadenylation sites of the expression cassettes and thus could not amplify any wild-type adenovirus. Primers for the first PCR were 5 0 -cggccggaggtaagtatcaa-3 0 and 5 0 -ccagatcttcgatgctagac-3 0 , and amplified a 300 bp fragment, which could not be detected on EtBr-stained agarose gels. Primers for the second PCR were 5 0 -ggcttgtcgagacagaga-3 0 and 5 0 -gttgctcgaagtcgagac-3 0 , and amplified a 100 bp fragment. Each PCR consisted of 25 cycles, 4% of the first PCR reaction was reamplified by the nested PCR reaction.
